Broad clinical involvement in a family affected by the fragile X premutation by Chonchaiya, W et al.
Broad Clinical Involvement in a Family Affected by the Fragile X
Premutation
WEERASAK CHONCHAIYA, M.D.,
M.I.N.D. Institute, University of California-Davis Medical Center, Sacramento, CaliforniaDivision of
Growth and Development, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University,
Bangkok, Thailand
AGUSTINI UTARI, M.D.,
M.I.N.D. Institute, University of California-Davis Medical Center, Sacramento, CaliforniaDivision of
Human Genetics, Center for Biomedical Research, Faculty of Medicine, Diponegoro University,
Semarang, Indonesia
GABRIELA MARQUES PEREIRA, M.D.,
Department of Pediatrics, São Marcos Hospital, Braga, Portugal
FLORA TASSONE, PH.D.,
M.I.N.D. Institute, University of California-Davis Medical Center, Sacramento, CaliforniaDepartment
of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Davis,
California
DAVID HESSL, PH.D., and
M.I.N.D. Institute, University of California-Davis Medical Center, Sacramento, CaliforniaDepartment
of Psychiatry and Behavioral Sciences, University of California-Davis Medical Center, Sacramento,
California
RANDI J. HAGERMAN, M.D.
M.I.N.D. Institute, University of California-Davis Medical Center, Sacramento, CaliforniaDepartment
of Pediatrics, University of California-Davis Medical Center, Sacramento, California
Abstract
The mutations in the FMR1 gene have been described as a family of disorders called fragile X-
associated disorders (FXD) including fragile X syndrome (FXS), fragile X-associated tremor/ ataxia
syndrome (FXTAS), primary ovarian insufficiency and other problems associated with the
premutation, such as hypothyroidism, hypertension, neuropathy, anxiety, depression, attention
deficit hyperactivity disorders and autism spectrum disorders. The premutation is relatively common
in the general population affecting 1 of 130–250 female individuals and 1 of 250–800 male
individuals. Therefore, to provide appropriate treatment and genetic counseling for all of the carriers
and affected individuals in a family, a detailed family history that reviews many of the disorders that
are related to both the premutation and the full mutation should be carried out as exemplified in these
cases.
To facilitate the integration of this knowledge into clinical practice, this is the first case report that
demonstrates only premutation involvement across 3 generations.
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Fragile X syndrome (FXS) is the most common known single gene cause of Autism Spectrum
Disorders (ASD) and inherited intellectual disabilities (ID). FXS is one of a family of fragile
X-associated disorders (FXD) caused by CGG-repeat expansion mutations of the fragile X
mental retardation 1 (FMR1) gene at chromosome Xq27.3.1 Over 200 CGG repeats have been
well described as the full mutation leading to an absence or deficiency of the fragile X mental
retardation protein (FMRP). The full mutation causes the physical, behavioral, cognitive and
emotional features of FXS.2,3 For a long time after the discovery of the FMR1 gene in 1991
individuals who have the fragile X premutation (55–200 CGG repeats) or gray zone alleles
(45–54 CGG repeats) were thought to be clinically uninvolved by the mutation. However,
advances in research in fragile X over the years have identified clinical involvement in some
premutation carriers including developmental problems, such as ADHD and ASD particularly
in boys,4,5 medical problems e.g. hypothyroidism, hypertension, fibromyalgia,6 seizures,7
menstrual dysfunction (primary ovarian insufficiency (POI))8 and psychological issues such
as depression and anxiety9–11 and late onset neurological problems described as the fragile
X-associated tremor ataxia syndrome (FXTAS).12,13 The premutation is associated with
elevated FMR1-mRNA from 2 to 8 times above normal and this leads to RNA toxicity which
is the molecular mechanism for clinical involvement in premutation carriers.14,15 Likewise, in
the gray zone there can be more subtle increases in FMR1-mRNA levels up to almost 1.5 times
normal when compared to controls.16 Clinical studies have shown that POI occurs twice as
often in women who carried alleles in the gray zone compared to general population suggesting
clinical attention should be warranted even in those with gray zone CGG expansions (45–54
CGG repeats).17,18 However, neurological and psychiatric problems have not been studied in
individuals with gray zone alleles. To facilitate the integration of premutation involvement into
clinical practice we report on three generations in a family in whom all cases of the fragile X
mutation including the proband and those identified by cascade testing, were affected by
premutation involvement. At least six individuals throughout 3 generations in this extended
family have been confirmed with the fragile X premutation and were evaluated at our center.
The terms, “carrier” and “premutation” have similar meaning and were used interchangeably
in this article.
CASE DESCRIPTIONS
Clinical Presentation
The proband is a 12-year and 6-month-old boy who developed language delay and social
deficits and was diagnosed with Pervasive Developmental Disorder-Not Otherwise Specified
(PDD-NOS) when he was three years of age and then subsequently was diagnosed with full
autism at 7 years of age. Due to the diagnosis of ASD, genetic testing including fragile X DNA
test was done. He was found to be a premutation carrier (63 CGG repeats) at four years of age
and was confirmed to have 61 CGG repeats at 7 years of age at our center.
He had typical behaviors of fragile X and autism including excessive chewing on clothes or
objects, skin picking, tactile defensiveness, hyperactivity, anxiety, perseverative behaviors,
tantrums and limited eye contact.
Prenatal, Perinatal and Postnatal History
His mother experienced prolonged labor coupled with heart rate decelerations and he was born
full term, vaginal delivery with an Apgar score of 7 and 9. In infancy, he did not feed well
because of a weak suck.
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Developmental History
His gross motor milestones were normal; he sat at 6 months, crawled at 8 months and walked
at 10 months, but his speech was delayed. He did not begin talking meaningful words until
after he started language intervention when he was almost 4 years.
Medical History Including Medications
His past medical history included an umbilical hernia, a few uncomplicated ear infections and
staring spells. The latter problem began when he was five years old. An EEG demonstrated
generalized poly-spike-wave discharges particularly during sleep. Valproic acid was
prescribed and he subsequently improved the frequency of his spontaneous speech. His staring
episodes decreased and behaviors became more attentive on valproic acid. He began speaking
in sentences at five years after seizures were controlled. When he was 9 yo lamotrigine was
added to valproic acid because of break through seizures which were subsequently controlled.
Other medications were tried because of his autism and hyperactivity including risperidone,
olanzapine and guanfacine. He developed more hyperactivity after taking risperidone and had
significant sedation after taking olanzapine. Aripiprazole was tried to control tantrums,
aggression, anxiety and distractibility but he developed a sleep disturbance on this so it was
discontinued. Risperidone has been the most beneficial for his mood instability, irritability and
tantrums. He has been on guanfacine for several years and this was noted to improve his
hyperactivity. However, it was discontinued when he started lamotrigine to decrease the
number of his medications. Melatonin at bedtime has helped him sleep through the night.
Physical Examination
On physical examination at 7 years of age, heart rate was 120 beats per minute. Blood pressure
was 106/70 mmHg. His growth percentiles were normal with a head circumference of 52.5
cm. (50th percentile). He had very limited eye contact, difficulty with social interaction and
intermittently made a high-pitched noise during the exam. He had a high-arched palate, a
double-jointed thumb on the left and flat feet bilaterally. Genitalia showed normal pre-pubertal
development with a testicular volume of 5 ml bilaterally. The rest of his physical examination
was unremarkable.
Additional Assessments
The Leiter International Performance Scale demonstrated a moderate range of ID with a Full
Scale IQ (FSIQ) of 46. The Vineland Adaptive Behavior Scales (VABS) completed with his
parents yielded standard scores of 40 in Communication (age equivalent 1 year 7 months), 37
in Daily Living Skills (age equivalent 2 years 7 months), 53 in Socialization (age equivalent
1 year 10 months) and 40 on the Adaptive Behavioral Composite (age equivalent 2 years). He
met the criteria for autism on the Autism Diagnostic Interview, Revised (ADI-R) and the
criteria set forth in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV).
Supports and Therapies
He has been in an autism program at school, which included typically developing children. He
also received speech and language therapy, sensory integration therapy, occupational therapy
(OT) along with behavioral intervention from the school. His current treatments include the
combination of speech and language therapy along with OT and horseback riding for an hour
each per week. His current medications include 0.5 mg. of risperidone, 1,450 mg. of valproic
acid, 150 mg. of lamotrigine per day and 9 mg of melatonin at bedtime.
Family members who were evaluated at our center including his maternal grandfather’s brother
(A), maternal grandfather (B), mother (C), both maternal aunts (D, E), biological brother (F)
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and cousin (G) are described in details in Table 1 and a summarized pedigree of this family is
illustrated in Figure 1. Two known non-carrier members in this family including the proband’s
father and maternal grandmother were also evaluated here. The biological father had
hyperactivity and reading difficulties that required tutoring when he was young, but he was
not diagnosed with ADHD nor treated with stimulants. The maternal grandmother had high
blood pressure and depression in the past, the latter problem began after her husband was
diagnosed with FXTAS. Otherwise, they both were healthy and had a normal IQ without any
other current psychological diagnoses.
DISCUSSION
This family demonstrated various types of the premutation involvement without any
individuals with the full mutation. Premutation involvement is a relatively new concept for
clinicians and it deserves further review so that it can be incorporated into screening and
treatment endeavors of physicians. Data in the literature which compares those with the
premutation to controls without the premutation will be reviewed to further validate whether
these problems are associated with the premutation.
Physical Involvement
The proband, his brother and cousin have at least one of the subtle physical features associated
with FXS, such as flat feet, a high arched palate, pectus excavatum and a double jointed thumb,
which can often be seen with the premutation because the level of FMRP can sometimes be
deficient in the premutation range.2,5 Although these physical features are also common in the
general population, hyperextensibility of finger joints, ear prominence and enlarged testicles
can also be presented in individuals with the premutation and these features are correlated with
FMRP levels in both the premutation and the full mutation.2,5,19–21
Developmental and Behavioral Involvement
Although the presence of autism in those with the full mutation has been thoroughly studied
this is not true of those with the premutation. Two to six percent of children with autism of
unknown etiology will have the fragile X full mutation22–24 but the rate of the premutation in
autism is not known. Approximately 30% of children with the full mutation and FXS will have
autism25,26 and an additional 30% will have PDD-NOS.27 Developmental and behavioral
problems including developmental delay, speech and language impairments, ASD, ADHD,
and social deficits, are relatively common in young individuals with the premutation
particularly in boys as reported in the literature.4,5,28–30 Farzin et al. (2006) found that ASD
and ADHD was significantly more common in boys with the premutation who presented as
probands compared to their brothers without the premutation.4 In a large survey study of over
1,200 fragile X families it was found that 45% of male individuals over 6 years of age with the
premutation had been diagnosed or treated for attention problems, 36% for anxiety, 32% for
developmental delay, 30% for hyperactivity and 19% for autism and aggression.7
Cognitive Involvement
Although cognitive deficits and even dementia are common in individuals with FXTAS,9,31
other cognitive deficits including executive function, working memory, selective attention and
social cognition have been demonstrated across the lifespan in premutation carriers without
FXTAS compared to controls.21,31–37 One exception to these reports is a study by Hunter et
al. (2008) who found no cognitive deficits in a cohort of individuals with the premutation who
were younger than age 50 compared to controls.38 Most individuals do well with the
premutation during early life and are able to overcome ADHD or social deficits to go on to
higher education.39
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Interesting work has been done in relating the cognitive impairments in premutation carriers
without FXTAS to neuroimaging findings suggesting a strong relationship among gene, brain
and cognitive profiles. For instance, decreased amygdala activation while viewing fearful
human faces, or decreased left hippocampal activation in addition to increased right parietal
activation during a recall task when compared to controls have been illustrated in men with
the premutation but without FXTAS.40,41 These functional changes were associated with both
elevated FMR1 RNA and psychiatric symptoms in these men. These findings suggest that the
connectivity in the brain linked to the amygdala and the hippocampus in those with the
premutation is mildly dysfunctional from a neurodevelopmental perspective and may
contribute to clinically signficicant impairment especially in those with higher CGG repeat
alleles. Studies of premutation neuron cell cultures have shown that branching of the dendrites
is decreased and the synaptic size is increased in neurons with the premutation compared to
controls.42 These connectivity changes likely make the individual with the premutation more
vulnerable to additional genetic or environmental problems that further interfere with
development. We also know that the premutation neuron will die more easily with toxicity or
stress in the environment so these cells are more vulnerable because of the RNA toxicity.43,44
Those with the premutation usually have a normal IQ, but this proband’s IQ was in a moderate
range of ID. This is a more of significant deficit than what is typically seen in premutation
carriers and in contrast to his brother’s higher level of function, so additional additive effects
must be considered here such as the proband’s history of recurrent seizures in addition to
autism.4,5,45 ID has been documented in male individuals with the premutation in previous
literature5,15,46,47 and the prevalence of ID was approximately 12% as reported in one large
study.46 The effect of each factor including severe social impairment, seizures comorbidity,
perhaps a second gene effect, and other environmental factors can be additive to the
premutation to predispose this proband to have more intellectually impaired when compared
to his biological brother even though they both have similar range of CGG repeats. Taken
together, CGG repeats alone do not predict or determine the entire outcome of those with fragile
X mutations. To improve the long-term outcome, early multidisciplinary management
including early intervention, speech and language therapy, occupational therapy, physical
therapy, special education, tailored behavioral and medical interventions should be
recommended particularly in those who have behavioral and neurodevelopmental problems.
48,49
Neurological Involvement
Seizures have been reported to be increased in those with autism and FXS compared to FXS
without autism.50 Seizures are more likely to occur in males with the premutation compared
to controls when matched on children’s age and family income (11.3% vs. 1.2%) in a recent
large survey study.7 This proband had seizures and a clinical response to valproic acid with
improvement in seizures in addition to language abilities and social skills. Such a response is
often seen in those with a full mutation and seizures48,49 and also in the autism population
without fragile X syndrome.51 Anticonvulsants should be part of the treatment program in
those with the fragile X mutation (premutation or full mutation) and clinical seizures.48,49
FXTAS, a progressive late onset neurological disorder has been documented for years in a
subgroup of older individuals with the premutation affecting some carriers over 50 years of
age.12 The proband’s maternal grandfather was diagnosed with probable FXTAS because of
his tremors and other symptoms52 and his FMR1 testing showed premutation mosaicism with
allele sizes of 52 and 68 CGG repeats. FXTAS features include intention tremor and/ or gait
ataxia, peripheral neuropathy, parkinsonism, psychiatric symptoms including anxiety,
irritability, or disinhibition, autonomic dysregulation including hypertension, orthostatic
hypotension and incontinence, executive function and memory deficits.13,31,37,52 In cases of
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FXTAS, 60% of males and 13% of females have an MRI with symmetric white matter lesions
involving the middle cerebellar peduncles (MCP sign).53 Presence of intranuclear inclusions
in both neurons and astrocytes throughout the brain are also reported from post-mortem
neuropathological studies of those with FXTAS.54 The maternal grandfather’s brother also
had a gray zone allele with 52 repeats and he had subtle tremor and balance problems but they
were not of the severity of what is typically seen in FXTAS (See Table 1). We do not yet know
whether neurological problems are more common in those with a gray zone allele.
Medical and Endocrinological Involvement
There is an increased risk for medical and endocrinological problems in individuals with the
premutation compared to age matched controls.6,55 The proband’s mother and one maternal
aunt had thyroid problems and another maternal aunt had hypertension and both conditions
have a higher prevalence in female carriers with neurological symptoms compared to controls.
6 These findings have been replicated in a subsequent study56 although an earlier study did not
report these medical problems, but many of these problems were not specifically questioned.
57 POI has been well validated by many studies as increased in premutation carriers compared
to controls.8,55,58 POI affects approximately 20% of female carriers but was not seen in the 3
females we evaluated here.
Psychological Involvement
The biological brother and cousin of the proband developed an overanxious disorder and
obsessive compulsive rituals. Likewise, mother and both maternal aunts of the proband
experienced anxiety and depression, which are more common in the premutation carriers,
varying from 18–43% in numerous studies of carriers compared to controls.9–11,59,60
Furthermore, psychological difficulties in those with the premutation were significantly
associated with elevated FMR1-mRNA level suggesting FMR1 dysfunction is an important
pathogenic mechanism of these problems, over and above the well-known stresses associated
with caring for children with intellectual impairment.11,59,60
Mechanism of Clinical Involvement in the Premutation
As we described in the introduction, the mechanism of the premutation involvement is different
from those with the full mutation in that an RNA toxic gain-of-function effect is seen due to
enhanced levels of FMR1 mRNA (2–8 times higher than normal individuals). The elevated
mRNA levels leads to dysregulation of several proteins and subsequent neuronal and astrocyte
toxicity and eventually cell death.15,43 The mRNA toxicity can involve many areas in the CNS
including the limbic system, pituitary, the autonomic ganglia of the peripheral nervous system
in addition to the testicles, thyroid and adrenal gland.61,62 Therefore, the elevated mRNA in
the maternal grandfather’s case is likely leading to the symptoms of FXTAS including head
and hands tremors, hypertension, hypoglycemic episodes, sleep apnea and anxiety although
he does not have the MCP sign.
Signs of premutation involvement including psychopathology, endocrine dysfunction,
autonomic dysfunction, and neuropathy typically occur even before the FXTAS problems of
tremor and ataxia begin. The fragile X or FMR1 DNA test should be considered in individuals
at high risk of having fragile X mutations particularly in children with ASD, developmental
and intellectual disabilities, women with early menopause, or older adults with intention tremor
or ataxia.63 This family tree is unusual because there is only premutation and gray zone
involvement. With more widespread screening for fragile X mutations we predict many more
similar pedigrees with significant premutation involvement will be seen because the
premutation is far more prevalent (1/250–800) than the full mutation (1/2500–4000).64
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In conclusion, there is often a wide range of clinical involvement in extended family members
in all generations when a proband is identified with a fragile X mutation. Therefore, to provide
appropriate treatment and genetic counseling for all of the affected individuals in a family, a
detailed family history that reviews many of the disorders that are related to both the
premutation and the full mutation should be carried out in addition to referral to a genetic
counselor and multidisciplinary professionals as necessary.48,65 Early treatment of
premutation and full mutation disorders are likely to be beneficial for their long-term outcome.
13,48
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Figure 1.
A summarized pedigree of a family with fragile X mutation demonstrating a broad spectrum
of clinical involvement throughout generations
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